

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/785, 45/06, A61P 9/10	A1	(11) International Publication Number: WO 00/69445 (43) International Publication Date: 23 November 2000 (23.11.00)
(21) International Application Number: PCT/US99/10568 (22) International Filing Date: 13 May 1999 (13.05.99) (71) Applicant: GELTEX PHARMACEUTICALS, INC. [US/US]; Nine Fourth Avenue, Waltham, MA 02154 (US). (72) Inventors: HUVAL, Chad, Cori; Apartment #9, 31 Walnut Street, Somerville, MA 02143 (US). HOLMES-FARLEY, Stephen, Randall; 20 Norfolk Road, Arlington, MA 02474 (US). PETERSEN, John, S.; 1 Bellantoni Drive, Acton, MA 01720 (US). DHAL, Pradeep, K.; 284 Great Road, No. C6, Acton, MA 01720 (US). (74) Agents: ELMORE, Carolyn, S. et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02421 (US).	(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>	
(54) Title: COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA (57) Abstract The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

-1-

COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA

BACKGROUND OF THE INVENTION

Reabsorption of bile acids from the intestine conserves lipoprotein cholesterol in the bloodstream. Conversely, blood cholesterol levels can be
5 diminished by reducing reabsorption of bile acids.

One method of reducing the amount of bile acids that are reabsorbed and, thus, reducing serum cholesterol is the oral administration of compounds that sequester the bile acids and cannot themselves be absorbed. The sequestered bile acids are excreted.

10 Compounds which have been suggested for bile acid sequestration include various ion exchange polymers. One such polymer is cholestyramine, a copolymer of divinylbenzene and trimethylammoniummethyl styrene. It has been long recognized that this polymer is unpalatable, gritty, and constipating. More recently, various polymers have been suggested which are characterized by hydrophobic
15 substituents and quaternary ammonium radicals substituted upon an amine polymer backbone (Ahlers, *et al.* U.S. Patent 5,428,112 and 5,430,110 and McTaggart, *et al.*, U.S. Patent 5,462,730, which are incorporated herein by reference). In some cases, these polymers have had disappointing efficacy and require complex processes for their manufacture.

20 Fibrates are also a known class of compounds which has been used as cholesterol-lowering agents. Fibrates are peroxisome proliferator-activated receptor antagonist that effectively lower plasma triglycerides by increasing VLDL lipolysis and clearance, and by decreasing hepatic VLDL triglyceride output. Fibrate treatment also raises HDL levels by increasing hepatic HDL synthesis. Examples of
25 fibrates include, Clofibrate (ATROMID-S®), Gemfibrozil (LOPID®), Fenofibrate, Bezafibrate and the compounds listed in Table 1.

-2-

Another class of compounds which have been used as cholesterol-lowering agents are nicotinic acid, commonly referred to as niacin, and derivatives thereof. Niacin is a potent triglyceride reducing agent with an HDL-elevating effect. Niacin therapy is prescribed to treat patients with moderate to severe hypertriglyceridemia and does not usually produce a significant LDL cholesterol-lowering effect. Niacin acts within the liver to decrease VLDL triglyceride output and in the periphery to increase its clearance. The side effects of niacin are well-known and usually limit usage. For example, high doses cause pruritis and flushing. In addition, an elevation in liver enzymes, abdominal cramps, diarrhea, nausea and vomiting have been observed. Niacin is available, for example, as NICOLAR® tablets. Nicotinic acid derivatives include, Acipimox, Aluminum Nicotinate, Niceritrol, Nicoclonate, Nicomol and Oxiniacic Acid.

Another class of compounds which are useful in cholesterol-lowering therapy are thyroid hormones and analogs such as Etiroxate, Thyropropic Acid and Thyroxine.

In addition, there are many known cholesterol-lowering agents which are not members of a particular class of agents. These other cholesterol-lowering agents include, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin.

The present invention furthers efforts for treating hypercholesterolemia and atherosclerosis, as well reducing serum cholesterol, by providing a combination therapy approach and a novel pharmaceutical composition useful therefor.

SUMMARY OF THE INVENTION

The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid



-3-

sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent selected from the group consisting of fibrates, nicotinic acid and derivatives thereof, and other cholesterol-lowering agents such as Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, and combinations thereof. The first and second amounts together comprise a therapeutically effective amount. Further, the combination therapy can also include HMG CoA reductase inhibitors such as those described in U.S. Patent Application No. _____ (Attorney Docket No. GTX97-23A, entitled, Combination Therapy for Treating Hypercholesterolemia, by C. Huval, S. Holmes-Farley, J. Petersen and P. Dhal) being filed concurrently, the entire content of which is incorporated herein by reference.

The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent selected from the group consisting of fibrates, nicotinic acid and derivatives thereof, and other cholesterol-lowering agents such as Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, and combinations thereof. The first and second amounts together comprise a therapeutically effective amount. Further, the pharmaceutical compositions can also include HMG CoA reductase inhibitors such as those described in U.S. Patent Application No. _____ (Attorney Docket No. GTX97-23A, entitled, Combination Therapy for Treating Hypercholesterolemia,

by C. Huval, S. Holmes-Farley, J. Petersen and P. Dhal) being filed concurrently, the entire content of which is incorporated herein by reference. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.

- 5 The unsubstituted polydiallylamine polymers are characterized by one or more monomeric units of the formulae:



- or a combination thereof and salts thereof. The polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial
10 absence of one or more trialkylammonium alkyl groups. The polymers are non-absorbable and optionally crosslinked. In preferred embodiments, the polymer is crosslinked by means of a multifunctional crosslinking agent. The polymer can also be characterized as being linear or branched.

- Each compound is present in the pharmaceutical composition in an amount
15 which in combination with the other provides a therapeutically effective amount. The pharmaceutical composition can include one or more of each compound.

Other features and advantages will be apparent from the following description of the preferred embodiments thereof and from the claims.

DETAILED DESCRIPTION OF THE INVENTION

The features and other details of the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principal features of the invention can be employed in various embodiments without departing from the scope of the present invention.


The invention provides methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent selected from the group consisting of fibrates, nicotinic acid and derivatives thereof, and other cholesterol-lowering agents such as Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, and combinations thereof. The first and second amounts together comprise a therapeutically effective amount. Further, the combination therapy can include HMG CoA reductase inhibitors such as those described in U.S. Patent Application No. _____ (Attorney Docket No. GTX97-23A, entitled, Combination Therapy for Treating Hypercholesterolemia, by C. Huval, S. Holmes-Farley, J. Petersen and P. Dhal) being filed concurrently, the entire content of which is incorporated herein by reference.

As used herein, the term "cholesterol-lowering agent" is intended to mean an agent selected from the group consisting of fibrates, nicotinic acid and derivatives thereof, and the following cholesterol-lowering agents: Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozadil, Probucol, B-Sitosterol,


Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, and combinations thereof.

As used herein, the term "therapeutically effective amount" is intended to qualify the combined amount of the first and second compounds in the combination therapy. The combined amount will achieve the desired biological response. In the present invention, the desired biological response can be the treatment of hypercholesterolemia, the treatment of atherosclerosis and/or a reduction of serum cholesterol. The mammal can be a human.

The unsubstituted polydiallylamine polymers are characterized by one or more monomeric units of the formulae:



(I)



(II)

or a combination thereof and salts thereof. The polymer can be characterized by the substantial absence of one or more alkylated amine monomers and/or the substantial absence of one or more trialkylammonium alkyl groups. The polymers are non-absorbable and optionally crosslinked. In preferred embodiments, the polymer is crosslinked by means of a multifunctional crosslinking agent. The polymer can also be characterized as being linear or branched.

As described above, the polymers employed in the method and pharmaceutical composition described herein comprise non-absorbable, optionally cross-linked polydiallylamines characterized by the formula above. Importantly, the polymers can be characterized by the substantial absence of substituted or unsubstituted alkyl substituents on the amino group of the monomer, such as obtained in the alkylation of an amine polymer. That is, the polymer can be characterized in that the polymer is substantially free of alkylated amine monomers.

The polymer can be a homopolymer or a copolymer. Where copolymers are manufactured with a diallylamine monomer, the comonomers are preferably inert, non-toxic and/or possess bile acid sequestration properties. Suitable examples of additional comonomers include substituted and unsubstituted acrylate, substituted and unsubstituted acrylamide, substituted and unsubstituted methacrylate, substituted and unsubstituted methacrylamide, allylamine, triallylamine, allyl alcohol, substituted and unsubstituted vinyl amine and substituted and unsubstituted vinyl alcohol. In one embodiment, the additional monomer is sulfur dioxide. Preferably, the monomers are aliphatic. Most preferably, the polymer is a homopolymer, i.e. a homopolydiallylamine.

Preferably, the polymer is rendered water-insoluble by branching and/or crosslinking. The cross-linking agent can be characterized by functional groups which react with the amino group of the monomer. Alternatively, the crosslinking group can be characterized by two or more vinyl groups which undergo free radical polymerization with the amine monomer. Suitable multifunctional co-monomers include triallylamine, tetraallylammonium salts, bis(diallylamine)s (such as alkylene bis(diallylamine)s), diacrylates, triacrylates and tetraacrylates, dimethacrylates, diacrylamides, diallylacrylamide and di(methacrylamides). Specific examples include ethylene bis(diallylamine), hexamethylene bis(diallylamine), ethylene glycol diacrylate, propylene glycol diacrylate, butylene glycol diacrylate, ethylene glycol dimethacrylate, butylene glycol dimethacrylate, methylene bis(methacrylamide), ethylene bis(acrylamide), ethylene bis(methacrylamide), ethylidene bis(acrylamide), ethylidene bis(methacrylamide), pentaerythritol tetraacrylate, trimethylolpropane triacrylate, bisphenol A dimethacrylate, and bisphenol A diacrylate. Other suitable multifunctional monomers include polyvinylarenes, such as divinylbenzene.

The polymer can alternatively be crosslinked by bridging units which link amino groups on adjacent polymer strands. Suitable bridging units include straight chain or branched, substituted or unsubstituted alkylene groups, diacylalkylene groups, diacylarene groups and alkylene bis(carbamoyl) groups. Examples of suitable bridging units include $-(CH_2)_n-$, wherein n is an integer from about 2 to about 20;

-8-

-CH₂-CH(OH)-CH₂-; -C(O)CH₂CH₂C(O)-; -CH₂-CH(OH)-O-(CH₂)_n-O-CH(OH)-CH₂-
5 , wherein n is 2 to about 4; -C(O)-(C₆H₄(COOH)₂)-C(O)- and -
C(O)NH(CH₂)_pNHC(O)-wherein p is an integer from about 2 to about 20.

Examples of suitable crosslinking agents include acryloyl chloride,
5 epichlorohydrin, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, and dimethyl
succinate.

A preferred crosslinking agent is epichlorohydrin because of its high
availability and low cost. Epichlorohydrin is also advantageous because of its low
molecular weight and hydrophilic nature, increasing the water-swellability of the
10 polyamine.

The level of crosslinking makes the polymers insoluble and substantially
resistant to absorption and degradation, thereby limiting the activity of the polymer to
the gastrointestinal tract. Thus, the compositions are non-systemic in their activity
and will lead to reduced side-effects in the patient. Typically, the cross-linking agent
15 is present in an amount from about 0.5-50% (more preferably about 0.5-30% and most
preferably about 2-20%) by weight, based upon total weight of monomer plus
crosslinking agent.

When used in a non-crosslinked form, polymers of use in the present method
are, preferably, of a molecular weight which enables them to reach and remain in the
20 gastrointestinal tract for a sufficient period of time to bind a significant amount of one
or more bile acids. These polymers should, thus, be of sufficiently high molecular
weight to resist, partially or completely, absorption from the gastrointestinal tract into
other regions of the body. The resulting polymer/bile salt complex should then be
excreted from the body. Suitable linear (non-crosslinked) polymers have molecular
25 weights which range from about 2,000 Daltons to about 500,000 Daltons, preferably
from about 5,000 Daltons to about 150,000 Daltons. Crosslinked polymers, however,
are not generally characterized by molecular weight. The crosslinked polymers
discussed herein should be sufficiently crosslinked to resist adsorption from the
gastrointestinal tract.

30 As described above the polymer can be administered in the form of a salt, or as
a partial salt. By "salt" it is meant that the nitrogen groups in all or some of the repeat

units are protonated to create a positively charged nitrogen atom associated with a negatively charged counterion.

The anionic counterions can be selected to minimize adverse effects on the patient, as is more particularly described below. Examples of suitable counterions include Cl^- , Br^- , $\text{CH}_3\text{OSO}_3^-$, HSO_4^- , SO_4^{2-} , nitrate, HCO_3^- , CO_3^{2-} -acetate, lactate, phosphate, hydrophosphate, methanesulfonate, fumarate, malate, pyruvate, malonate, benzoate, glucuronate, oxalate, acetylglycinate, succinate, propionate, butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino acid derivative, a nucleotide, a lipid, or a phospholipid. The counterions can be the same as, or different from, each other. For example, the reaction product can contain two different types of counterions.

Polymers of use in the present method can be prepared using techniques known in the art of polymer synthesis (see for example, Shalaby *et al.*, ed., *Water-Soluble Polymers*, American Chemical Society, Washington D.C. (1991)). For example, the appropriate monomer(s) can be polymerized by methods known in the art, for example, via a free radical addition process. In this case the polymerization mixture includes a free-radical initiator, such as a free radical initiator selected from among those which are well known in the art of polymer chemistry. Suitable free-radical initiators include azobis(isobutyronitrile), azobis(4-cyanovaleric acid), azobis(amidinopropane) dihydrochloride, potassium persulfate, ammonium persulfate and potassium hydrogen persulfate. The free radical initiator is preferably present in the reaction mixture in an amount ranging from about 0.1 mole percent to about 5 mole percent relative to the monomer.

The polymer can be crosslinked, for example, by including a multifunctional co-monomer as the crosslinking agent in the reaction mixture. A multifunctional co-monomer can be incorporated into two or more growing polymer chains, thereby crosslinking the chains. Suitable multifunctional co-monomers include those discussed above.

The polymers can also be crosslinked subsequent to polymerization by reacting the polymer with one or more crosslinking agents having two or more functional groups, such as electrophilic groups, which react with amine groups to

form a covalent bond. Crosslinking in this case can occur, for example, via nucleophilic attack of the polymer amino groups on the electrophilic groups. This results in the formation of a bridging unit which links two or more amino nitrogen atoms from different polymer strands. Suitable crosslinking agents of this type

5 include compounds having two or more groups selected from among acyl-X, epoxide, and alkyl-X, wherein X is a suitable leaving group, such as a halo, tosyl, mesyl, acyl or glycidyl group. Examples of such compounds include epichloro-hydrin, succinyl dichloride, butanedioldiglycidyl ether, ethanedioldiglycidyl ether, pyromellitic dianhydride and dihaloalkanes. The crosslinking agent can also be an α,ω -alkylene

10 diisocyanate, for example $\text{OCN}(\text{CH}_2)_p\text{NCO}$, wherein p is an integer from about 2 to about 20.

The polymer can also be crosslinked using a crosslinking agent which incorporates one functional group which incorporates into the polymerizing chain and a second functional group which can react with amine groups in a second polymer

15 chain. Examples include glycidyl methacrylate, glycidyl acrylate, acryloyl chloride, methacryloyl chloride, 3-bromopropylacrylate, 3-bromopropylmethyl-diallylammonium chloride, and 3-chloropropyl-diallylamine.

The Fibrates useful in the present invention are listed in Table 1. The Patent Nos. listed in Table 1 are incorporated herein by reference.

20 **TABLE 1**

<u>FIBRATES</u>	<u>ALTERNATIVE NAME</u>	<u>PATENT NO.</u>
Beclobrate	Beclipur; Turec	US 4,483,999
Bezafibrate	Benfizal; Benzalip; Bezato; Cedur; Difaterol	US 3,781,328
25 Binifibrate		
Ciprofibrate	Ciprol; Lipanor; Modalim	US 3,948,973
Clinofibrate	Lipoclin	US 3,716,583

-11-

	Clofibrate	Amotril; Anparton; Apolan; Artevil; Ateculon; Arteriosan; Atheroprone; Atromidin; Atromid-S; Biosclercan; Claripex; Clobren-SF; Clofinit; CPIB; Hyclorate; Liprinal; Neo-Atromid; Normet; Normolipol; Recolip; Regelan; Serotinx; Sklerolip; Skleromex; Sklero-Tablinen; Ticlobran; Xyduril	US 3,262,850
5			
	Clofibric Acid		GB 860,303
10	Etofibrate		US 3,723,446
	Fenofibrate	Ankebin; Elasterin; Fenobrate; Fenotard; Lipanthyl; Lipantil; Lipidil; Lipoclar; Lipofene, Liposit; Lipsin; Nolipax; Procetoken; Protolipan; Secalip	US 4,058,552
15	Gemfibrozil	Decrelip; Genlip; Gevilon; Lipozid; Lipur; Lopid	US 3,674,836
	Nicofibrate		US 3,369,025
	Pirifibrate		
	Ronifibrate	Bratenol	US 3,971,798
20	Simifibrate	Cholesolvin; Liposolvin	US 3,494,957
	Theofibrate	Duolip	US 3,984,413

The nicotinic acid and derivatives thereof which are useful in the present invention are Nicotinic Acid, also referred to as Niacin available, for example, as NICOLAR® tablets and Nicotinic acid derivatives: Acipimox, Aluminum

25 Nicotinate, Niceritrol, Nicoclonate, Nicomol and Oxiniacic Acid.

Thyroid hormones and analogs useful in the present invention include, but are not limited to, Etiroxate, Thyropropic Acid and Thyroxine.

Other cholesterol-lowering agents useful in the present invention include, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin

30 Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-

-12-

Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenylbutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin.

- 5 The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent selected from the group consisting of fibrates,
- 10 nicotinic acid and derivatives thereof, and other cholesterol-lowering agents such as Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -
- 15 phenylbutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, and combinations thereof. The first and second amounts together comprise a therapeutically effective amount. Further, the pharmaceutical compositions can include HMG CoA reductase inhibitors such as those described in U.S. Patent Application No. _____ (Attorney Docket No.
- 20 GTX97-23A, entitled, Combination Therapy for Treating Hypercholesterolemia, by C. Huval, S. Holmes-Farley, J. Petersen and P. Dhal) being filed concurrently, the entire content of which is incorporated herein by reference. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier. The first and second amounts of said compounds comprise a
- 25 therapeutically effective amount.

 In practicing the methods of the invention, combination therapy refers to administration of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent, as defined herein, and/or an HMG CoA reductase inhibitor to treat hypercholesterolemia and

30 atherosclerosis, and reduce serum cholesterol. Administration in combination therapy encompasses co-administration of the first and second amounts of the compounds of

the combination therapy in a single substantially simultaneous manner, such as in a single capsule or tablet having a fixed ratio of first and second amounts, or in multiple, separate capsules or tablets for each. In addition, such administration also encompasses use of each compound in a sequential manner.

5 Administration, of the cholesterol-lowering agent, and HMG CoA reductase inhibitor, when present, in combination therapy, may be accomplished by oral route, or by intravenous, intramuscular, subcutaneous injections or a combination thereof. The cholesterol-lowering agent and HMG CoA reductase inhibitor of the combination can be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile
10 injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, for example, saline, dextrose, water or a combination thereof, or a binder such as gelatin or hydroxypropylmethyl cellulose, together with one or more of a lubricant, preservative, surface active or dispersing agent.

15 For oral administration, all compounds used in the combination therapy can be in the form of, for example, a tablet, capsule, suspension, or liquid. Capsules, tablets, and the like can be prepared by conventional methods well known in the art. The compounds are preferably made in the form of a dosage unit containing a specified amount of the compound. Examples of dosage units are tablets or capsules.

20 Pharmaceutical compositions for use in the treatment methods of the present invention can be administered in oral form for all compounds of the composition, or by intravenous administration for the cholesterol-lowering agent and HMG CoA reductase inhibitor, when present. Oral administration of the pharmaceutical composition comprising the compounds of the combination therapy is preferred.

25 Dosing for oral administration can be with a regimen calling for single daily dose, or for a single dose every other day, or for multiple, spaced doses throughout the day.

The unsubstituted polydiallylamine polymer compound and the cholesterol-lowering agent which comprise the pharmaceutical composition can be administered simultaneously, either in a combined dosage form or in separate dosage forms
30 intended for substantially simultaneous oral administration. The agents which make up the pharmaceutical composition may also be administered sequentially, with either

-14-

compound being administered by a regimen calling for two-step ingestion. Thus, a regimen may call for sequential administration of the compound with spaced-apart ingestion of the separate, active compounds. The time period between the multiple ingestion steps may range from a few minutes to several hours, depending upon the properties of each compound such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the compound, as well as depending upon the age and condition of the patient. The compounds of the pharmaceutical composition whether administered simultaneously, substantially simultaneously, or sequentially, can involve a regimen calling for administration of the unsubstituted polydiallylamine polymer by oral route and cholesterol-lowering agent by intravenous route. Whether the agents of the pharmaceutical composition are administered by oral or intravenous route, separately or together, each compound can be contained in a suitable pharmaceutical formulation of pharmaceutically-acceptable excipients, diluents or other formulations as described above.

15 TREATMENT REGIMEN

The dosage regimen to treat hypercholesterolemia and atherosclerosis and reduce plasma cholesterol with the combination therapy and pharmaceutical compositions of the present invention is selected in accordance with a variety of factors. These include the type, age, weight, sex, diet, and medical condition of the patient, the severity of the disease, the route of administration, pharmacological consideration such as the activity, efficacy, pharmacokinetics and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized, and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore deviate from the preferred dosage regimen set forth above.

Initial treatment of a patient suffering from a hyperlipidemic condition such as hypercholesterolemia and atherosclerosis can begin with the dosages indicated above. Treatment should generally be continued as necessary over a period of several weeks to several months or years until the condition has been controlled or eliminated. Patients undergoing treatment with the compounds or compositions disclosed herein

can be routinely monitored by, for example, measuring serum LDL and total cholesterol levels by any of the methods well known in the art, to determine the effectiveness of the combination therapy. Continuous analysis of such data permits modification of the treatment regimen during therapy so that optimal effective
5 amounts of each type of agent are administered at any point in time, and so that the duration of treatment can be determined as well. In this way, the treatment regimen/dosing schedule can be rationally modified over the course of therapy so that the lowest amount of unsubstituted polydiallylamine bile acid sequestrant and cholesterol-lowering agent, as defined herein, which together exhibit therapeutic
10 effectiveness, is administered and so that administration is continued only so long as is necessary to successfully to treat the hyperlipidemic condition such as hypercholesterolemia and atherosclerosis.

A potential advantage of the combination therapy disclosed herein may be reduction of the first amount of unsubstituted polydiallylamine bile acid sequestrant,
15 second amount of other cholesterol-lowering agent or both, and/or HMG Co-A reductase inhibitor, when present, effective in treating hyperlipidemic conditions such as atherosclerosis and hypercholesterolemia, and in reducing serum cholesterol.

In the case of fibrates, the dose can range from about 0.02 g/day to about 2.5 g/day, more particularly from about 0.5 g to about 2.0 g, most particularly from about
20 1 g/day to about 2 g/day, or any other dose, depending upon the specific fibrate, as is normally employed in the art, for example, as indicated in the Physician's Desk Reference and The Merck Index (Twelfth Edition), the contents of both of which are incorporated herein by reference.

The unsubstituted polydiallylamine bile acid sequestrant compound can be
25 administered in an amount from about 1 mg/kg/day to about 10 g/kg/day, preferably from about 1 mg/kg/day to about 1 g/kg/day, more preferably from about 1 mg/kg/day to about 200 mg/kg/day, and most preferably from about 1 mg/kg/day to about 100 mg/kg/day.

In the case of niacin, and niacin/nicotinic acid derivatives the dose can range
30 from about 0.5 g/day to about 12 g/day, more particularly from about 1 g to about 8 g/day, or any other dose, depending upon the specific agent, as is normally employed

in the art, for example, as indicated in the Physician's Desk Reference and The Merck Index (Twelfth Edition), the contents of both of which are incorporated herein by reference.

For the thyroid hormones and analogs, Etiroxate, Thyropropic Acid and
5 Thyroxine, the dose would be that normally employed in the art, for example, as indicated in the Physician's Desk Reference and The Merck Index (Twelfth Edition), the contents of both of which are incorporated herein by reference.

With regard to the other cholesterol-lowering agents which include, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate,
10 Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol and Xenbucin, the dose would be that normally employed in the art, for example, as
15 indicated in the Physician's Desk Reference and The Merck Index (Twelfth Edition), the contents of both of which are incorporated herein by reference.

The particular dosage will depend on the individual patient (e.g., the patient's weight and the extent of bile salt removal required). The polymer can be administered either in hydrated or dehydrated form, and can be flavored or added to a food or drink,
20 if desired, to enhance patient acceptability. Additional ingredients such as other bile acid sequestrants, drugs for treating hypercholesterolemia, atherosclerosis or other related indications, or inert ingredients, such as artificial coloring agents can be added as well.

The first and second amounts of the compounds of the combination therapy
25 can be administered by any dual combination of oral/oral, oral/parenteral, or parenteral/parenteral route, respectively.

Examples of suitable forms for administration include pills, tablets, capsules, and powders (e.g., for sprinkling on food). The pill, tablet, capsule, or powder can be coated with a substance capable of protecting the composition from disintegration in
30 the esophagus but will allow disintegration of the composition in the stomach and mixing with food to pass into the patient's small intestine. The polymer can be

-17-

administered alone or in combination with a pharmaceutically acceptable carrier, diluent or excipient substance, such as a solid, liquid or semi-solid material.

Examples of suitable carriers, diluents and excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, alginates, tragacanth, gelatin,

5 calcium silicate, cellulose e.g., magnesium carbonate or a phospholipid with which the polymer can form a micelle.

The invention will now be described more specifically by the examples.

EXAMPLE 1: PREPARATION OF POLY(DIALLYLAMMONIUM CHLORIDE)

Concentrated hydrochloric acid (507.0 g; 37%) was charged to a 5L, 3-neck
10 round bottomed flask and agitated with a mechanical stirrer. The flask was cooled to <5°C with an ice bath. Diallylamine (635.0 ml) was added dropwise to the stirring hydrochloric acid over a three hour period using an addition funnel capped with a pierced rubber septum. The stirring solution temperature was maintained at <10°C. After the addition was completed, the ice bath was removed and the mixture was
15 allowed to warm to room temperature. Concentrated hydrochloric acid (7.3 g) was added to the solution. Water (368.7 g) was added to the solution and it was allowed to sit overnight.

The stirring solution was purged with nitrogen gas for 30 minutes at room temperature. 2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as
20 34.4 g of a 20% aqueous solution. The solution was heated to 60°-80°C for six and one-half hours. 2,2'-Azobis[2-amidinopropane] dihydrochloride (6.87g) was added as a 20% aqueous solution. The solution was stirred and heated overnight (16 hours).

2,2'-Azobis[2-amidinopropane]dihydrochloride (6.87 g) was added as a 20% aqueous solution. The solution was stirred and heated for another 16 hours, then
25 cooled to room temperature.

Sodium hydroxide (53.8 g) was dissolved in H₂O (2156 mL). The polydiallylamine-HCl solution was then added to the sodium hydroxide solution and agitated with a mechanical stirrer until dissolved. Concentrated hydrochloric acid (49.8 g; 37%) was added.

EXAMPLE 2: SYNTHESIS OF POLYDIALLYLAMINE

A solution of 39.3 g of an aqueous solution (68 wt%) of diallylammonium hydrochloride, 5.3 g of an aqueous solution (73 wt%) of triallylamine hydrochloride and 0.9 g of 2,2'-azobis(2-amidinopropane)dihydrochloride was bubbled with a slow stream of nitrogen for 30 minutes. While stirring, this reaction mixture was added to a solution of 7 g of polyvinylacetate in 300 mL of toluene. The resulting mixture was stirred at room temperature for 45 minutes under nitrogen atmosphere. While stirring, the temperature of the reaction mixture was raised to 60 C and was held at this temperature for 24 hours. The reaction mixture was allowed to cool to room temperature and the polymer particles were collected by filtration. While in the funnel, the filtered particles were successively washed with 300 mL of toluene and 500 mL of methanol. The polymer particles were suspended in 500 mL of methanol, stirred for 50 minutes, and filtered. Subsequently, the particles were suspended in 400 mL of deionized water, stirred for 30 minutes and filtered. The filtered particles were dried at 60 C for 24 hr to yield 15 g of the polymer.

EXAMPLE 3: CROSS-LINKED POLYDIALLYLAMINE

The polymer solution of Example 1 was crosslinked at 30 mole % as follows: Epichlorohydrin (31.61 mL) was added to 900.0 g of the neutralized polymer solution in a glass beaker, agitated with a magnetic stirrer and covered with polyvinyl film. The gel was allowed to cure for 22 hours. The solid gel was then ground using a grinder. The ground polymer was washed in a static bed manner using a large plastic Buchner funnel lined with filter paper. A second piece of filter paper, perforated with holes, was placed on top of the polymer cake to prevent disturbing the cake when adding wash water. Fresh deionized H₂O(14 L) was added to the top of the cake and drained under vacuum. The washed polymer was then transferred to glass drying trays and dried in a 60°C forced air oven for several days. The final dry weight was 176.2 g.

EXAMPLE 4: CROSSLINKED POLYDIALLYLAMINE

Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 20 mole %. Epichlorohydrin (21.07 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 163.3 g.

5 EXAMPLE 5: CROSSLINKED POLYDIALLYLAMINE

Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 10 mole %. Epichlorohydrin (10.54 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 164.2 g.

EXAMPLE 6: CROSSLINKED POLYDIALLYLAMINE

10 Using the same procedure as in Example 3, the neutralized polymer solution was crosslinked at 4.5 mole %. Epichlorohydrin (4.74 mL) was added to 900.0 g of the neutralized polymer solution. The final dry weight was 176.2 g.

EXAMPLE 7: COPOLYMER OF DIALLYLAMINE AND
METHYLENEBISACRYLAMIDE

15 A solution of diallylammonium chloride (73.53 g of 68% aqueous solution), methylenebisacrylamide (2.93 g, 0.019 mol), 2,2'-azobis(2-amidinopropane) dihydrochloride (V50) (0.5 g) and water (27 mL) was heated at 70°C under a nitrogen atmosphere. Water (100 mL) was added after 15 minutes of reaction. An additional 0.5 g of V50 was added after 3 hours and again after 4 more hours. After keeping the
20 reaction at 70 C for a total of 72 hr, it was cooled to room temperature. The resulting material was filtered and washed with 2 M NaCl (400 mL), and filtered and washed with water (2.5 L) and filtered again. The washed polymer was dried at 60°C in a forced-air oven gave 18.8 g of a solid (0.36 g/g yield, IPS=18.4)

EXAMPLE 8: COPOLYMER OF DIALLYLAMINE AND ACRYLAMIDE

25 A solution of diallylammonium chloride (73.53 g of 68% aqueous solution), methylenebisacrylamide (2.93 g, 0.019 mol), 2,2'-azobis(2-amidinopropane) dihydrochloride (0.5 g) and water (27 mL) was heated at 70°C under a nitrogen

-20-

atmosphere for 3 days. Water (100 mL) was added after the first 15 minutes of reaction. 2,2'-Azobis(2-amidinopropane)dihydrochloride (0.5 g) was added after 3 hours and 7 hours. The resulting material was filtered and washed with 2 M NaCl (400 mL) and water (2.5L). The washed polymer was dried at 60°C in a forced-air oven to give 18.8 g of a solid.

EXAMPLE 9: COPOLYMER OF DIALLYLAMINE, ACRYLAMIDE AND METHYLENEBISACRYLAMIDE

A solution of diallylammonium chloride (14.7 g of 68% aqueous), acrylamide (5.33 g), methylenebisacrylamide (2.31 g), MeOH (50 mL), and 2,2'-azobis(2-amidinopropane)dihydrochloride (0.07 g of an 18.8% solution of water) was heated at 65°C under a nitrogen atmosphere for 20 hours. The resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered. This methanol wash was repeated twice more. The washed polymer was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.4. Filtration, and drying at 60°C in a forced-air oven gave 9.8 g of a solid.

EXAMPLE 10: COPOLYMER OF DIALLYLAMINE, A FUNCTIONALIZED ACRYLIC ESTER AND AN ACRYLIC ESTER CROSS-LINKING MONOMER

A solution of diallylammonium chloride (14.7 g of 68% aqueous), 2-hydroxyethylmethacrylate (9.76 g), ethyleneglycol dimethacrylate (2.97 g), MeOH (25 mL), and 2,2'-azobis(2-amidinopropane) dihydrochloride (0.07 g of an 18.8% aqueous solution) was heated at 65°C under a nitrogen atmosphere for 20 hours. The resulting material was suspended in methanol (500 mL), stirred for 15 minutes and filtered. The polymer was similarly washed three times with water (500 mL). This methanol wash and filtration were repeated twice more. The washed polymer was suspended in water (500 mL) and this mixture was acidified with concentrated HCl to pH 2.1. Filtration and drying at 60°C in a forced-air oven gave 13.9 g of a solid.

EXAMPLE 11: COPOLYMER OF DIALLYLAMINE, A
FUNCTIONALIZED ACRYLIC ESTER AND AN ACRYLIC
ESTER CROSS-LINKING MONOMER

A solution of diallylammonium chloride (22.06 g of a 68% aqueous solution),
5 tetrahydrofurfuryl methacrylate (18.72 g), ethyleneglycol dimethacrylate (4.36 g) and
2,2'-azobis(2-amidinopropane) dihydrochloride (2.03 g of an 18.8% aqueous solution)
was heated at 65°C under a nitrogen atmosphere for 24 hours. The resulting material
was suspended in methanol (300 mL), stirred 15 minutes and filtered. This methanol
wash and filtration was repeated twice more. The polymer was similarly washed three
10 times with water (500mL). The material was suspended in water (500 mL) and this
mixture was acidified with concentrated HCl to pH 2.0. Filtration, and drying at 60°C
in a forced-air oven gave 19.9 g of a solid.

EXAMPLE 12: COPOLYMER OF DIALLYLAMINE AND
GLYCIDYLMETHACRYLATE

15 A solution of diallylammonium chloride (29.42 g of a 68% aqueous solution),
glycidylmethacrylate (2.13 g), MeOH (25 mL), and 2,2'-azobis(2-amidinopropane)
dihydrochloride (1.18 g of an 18.8% aqueous solution) was heated at 65°C under a
nitrogen atmosphere for 12 hours. After cooling to room temperature, methanol (25
mL) was added and the pH of the solution was adjusted to 10 with the addition of
20 50% aqueous NaOH, and allowed to stir at room temperature. The reaction solution
turned to a solid mass after about 2 hours, and was allowed to stand for 22 hours. The
resulting gel, was suspended in MeOH (300 mL), stirred and filtered. This methanol
wash and filtration were repeated twice more. The polymer was then suspended in
water (1 L). Concentrated HCl was added to this suspension until pH 2.0 and stirred
25 0.5 hours. Filtration and drying in a forced-air oven at 60°C gave 6.0 g of a solid.

-22-

EXAMPLE 13: COPOLYMER OF ALLYLAMINE, DIALLYLAMINE,
TRIALLYLAMINE AND A
BIS(DIALLYLAMINO)ALKYLENE SALT

A solution of allylammonium chloride (25.0 g of a 60% aqueous solution),
5 diallylammonium chloride (66.81 g of a 67% aqueous solution), triallylammonium
chloride (40.87 g of a 68% aqueous solution), 1,6-bis(diallylmethylammonium)
hexane dibromide (5.0 g), and 2,2'-azobis(2-amidinopropane) dihydrochloride
(4.28 g of a 20% aqueous solution), was heated at 55°C under a nitrogen atmosphere
for 18 hours and at 80°C for 2 hours. After cooling to room temperature, the gel was
10 suspended in MeOH (500 mL), stirred 15 minutes and filtered. This method was
repeated. The polymer was suspended in water (1.0 L) and stirred at least 15 minutes
and filtered. After drying in a 60°C forced-air oven, 31.9 g of solid was isolated.

EXAMPLE 14: COPOLYMER OF ALLYLAMINE AND DIALLYLAMINE

A solution of allylammonium chloride (54.71 g of a 57% aqueous solution),
15 diallylammonium chloride (132.96 g of a 67% aqueous solution), and 2,2'-azobis(2-
amidinopropane)dihydrochloride (6.01 g of a 20% aqueous solution), was heated at
55°C under a nitrogen atmosphere for 36 hours. Another portion of 2,2'-azobis(2-
amidinopropane)dihydrochloride (6.01 g of a 20% aqueous solution) was added after
the first 18 hours. After cooling to room temperature, the solution was added slowly
20 to IPA (3 L), and the precipitate after decanting the IPA layer, was washed with IPA
(3 L) and filtered. The precipitate was dried in a forced-air oven at 60°C to afford
106.9 g of a solid.

EXAMPLE 15: COPOLYMER OF ALLYLAMINE, DIALLYLAMINE AND
A BIS(DIALLYLAMINO) ALKYLENE

25 A solution of allylammonium chloride (27.36 g of a 57% aqueous solution),
diallylammonium chloride (66.48 g of a 67% aqueous solution), 1,6-bis(diallyl-
methylammonium) hexane dibromide (10.0 g), and 2,2'-Azobis(2-amidinopropane)
dihydrochloride (3.01 g of a 20% aqueous solution), was heated at 55°C under a
nitrogen atmosphere for 36 hours. Another portion of 2,2'-Azobis(2-amidino-

- propane) dihydrochloride (3.01 g of a 20% aqueous solution) was added after the first 18 hours. A gel formed after about 24 hours of heating. After cooling to room temperature, this material was washed with MeOH (500 mL) and filtered three times, as described above. The polymer was then suspended and washed with water (2.5 L).
- 5 After filtration, the wet material was dried in a forced-air oven at 60°C to afford 24.8 g of a solid.

EXAMPLE 16: *IN VIVO* TESTING

- Male Golden Syrian Hamsters were group housed in shoe box cages and acclimated for approximately 1 week in our animal facility. Animals were fed rodent
- 10 chow (brown color) and water ad libitum. The hamsters were then transferred to metabolism cages and housed individually. Following a 24 hour fast (water ad libitum), animals were presented a casein-based purified diet (white color) with 10% fat added plus the drug to be evaluated. Fecal material was collected from 9 hours after the casein-based diet was presented for 39 additional hours. The white fecal
- 15 pellets (drug-containing casein-based diet) were lyophilized and ground to a homogeneous powder. One gram of the ground fecal pellet was extracted in a solution consisting of methanol and 500 mM aqueous NaOH (4:1; v/v) at 100°C and 1500 psi for 15 minutes. A 500 μ L aliquot of the extract was evaporated and reconstituted in 1500 μ L bovine calf serum:0.9% saline (1:1) and analyzed
- 20 enzymatically, utilizing a test kit for bile acids (Sigma Chemical Co., St. Louis, MO) for bile acid concentration.

TABLE 2

Polymer	Dose (% in feed)	Fecal Bile Acids (μ mol/g)
None	None	1.34
25 Example 6	.10	2.19
Example 6	.15	3.44
Example 6	.20	3.72

-24-

Example 6	.25	3.48
Cholestyramine	0.30	3.00
Colestipol	0.30	2.81

This example shows that crosslinked polydiallylamine is a highly potent bile acid
5 sequestrant, with *in vivo* activity greater than current commercial products, Colestipol
and Cholestyramine.

EQUIVALENTS



Those skilled in the art will know, or be able to ascertain, using no more than
routine experimentation, many equivalents to the specific embodiments of the
10 invention described herein. These and all other equivalents are intended to be
encompassed by the following claims.

CLAIMS

What is claimed is:

1. A method for treating hypercholesterolemia comprising administering to said patient:
 - 5 a) a first amount of an unsubstituted polydiallylamine polymer; and
 - b) a second amount of a cholesterol-lowering agentwherein the first and second amounts together comprise a therapeutically effective amount.
- 10 2. The method of Claim 1 wherein the cholesterol-lowering agent is selected from the group consisting of: fibrates, nicotinic acid and derivatives thereof, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol
- 15 Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol, Xenbucin, and combinations thereof.
3. The method of Claim 1 wherein the cholesterol-lowering agent is a fibrate.
4. The method of Claim 3 wherein the fibrate is Clofibrate, Gemfibrozil,
- 20 Fenofibrate, Bezafibrate or combinations thereof.
5. The method of Claim 1 wherein the cholesterol-lowering agent is Niacin.
6. The method of Claim 1 wherein the cholesterol-lowering agent is Probucol.

7. The method of Claim 1 wherein the unsubstituted polydiallylamine is characterized by one or more monomeric units of the formulae:



or a combination thereof and salts thereof.

- 5 8. The method of Claim 1 wherein said polymer is crosslinked by means of a multifunctional crosslinking agent, said agent being present in an amount from about 0.5-50% by weight, based upon the combined weight of monomer and crosslinking agent.
9. The method of Claim 8 wherein said crosslinking agent is present in an
10 amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
10. The method of Claim 8 wherein said crosslinking agent comprises epichlorohydrin.
11. The method of Claim 8 wherein said crosslinking agent is a
15 bis(diallylammonium)dialkylene ion.
12. The method of Claim 1 wherein the polymer is a homopolymer.
13. A method of Claim 1 wherein the polymer is a copolymer.

14. A method of Claim 13 wherein the copolymer comprises the monomers diallylamine, allylamine, and triallylamine.
15. A method of Claim 13 wherein the copolymer comprises the monomers diallylamine and allylamine.
- 5 16. A pharmaceutical composition comprising:
 - a) a first amount of an unsubstituted polydiallylamine polymer;
 - b) a second amount of a cholesterol-lowering agent wherein said first and second amounts together comprise an effective amount; and
 - c) optionally, a pharmaceutically acceptable carrier.
- 10 17. The composition of Claim 16 wherein the cholesterol-lowering agent is selected from the group consisting of: fibrates, nicotinic acid and derivatives thereof, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol,
15 Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenylbutyramide, Priozadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol, Xenbucin, and combinations thereof.
18. The composition of Claim 16 wherein the cholesterol-lowering agent is a
20 fibrate.
19. The composition of Claim 18 wherein the fibrate is Clofibrate, Gemfibrozil, Fenofibrate, Bezafibrate or combinations thereof.
20. The composition of Claim 16 wherein the cholesterol-lowering agent is Niacin.

Example 6	.25	3.48
Cholestyramine	0.30	3.00
Colestipol	0.30	2.81

This example shows that crosslinked polydiallylamine is a highly potent bile acid
5 sequestrant, with *in vivo* activity greater than current commercial products, Colestipol
and Cholestyramine.

EQUIVALENTS



Those skilled in the art will know, or be able to ascertain, using no more than
routine experimentation, many equivalents to the specific embodiments of the
10 invention described herein. These and all other equivalents are intended to be
encompassed by the following claims.

CLAIMS

What is claimed is:

1. A method for treating hypercholesterolemia comprising administering to said patient:
 - 5 a) a first amount of an unsubstituted polydiallylamine polymer; and
 - b) a second amount of a cholesterol-lowering agentwherein the first and second amounts together comprise a therapeutically effective amount.
2. The method of Claim 1 wherein the cholesterol-lowering agent is selected
10 from the group consisting of: fibrates, nicotinic acid and derivatives thereof, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol, Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol
15 Tetraacetate, α -phenylbutyramide, Priozaol, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol, Xenbucin, and combinations thereof.
3. The method of Claim 1 wherein the cholesterol-lowering agent is a fibrate.
4. The method of Claim 3 wherein the fibrate is Clofibrate, Gemfibrozil,
20 Fenofibrate, Bezafibrate or combinations thereof.
5. The method of Claim 1 wherein the cholesterol-lowering agent is Niacin.
6. The method of Claim 1 wherein the cholesterol-lowering agent is Probucol.

7. The method of Claim 1 wherein the unsubstituted polydiallylamine is characterized by one or more monomeric units of the formulae:



or a combination thereof and salts thereof.



- 5 8. The method of Claim 1 wherein said polymer is crosslinked by means of a multifunctional crosslinking agent, said agent being present in an amount from about 0.5-50% by weight, based upon the combined weight of monomer and crosslinking agent.
- 10 9. The method of Claim 8 wherein said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
10. The method of Claim 8 wherein said crosslinking agent comprises epichlorohydrin.
11. The method of Claim 8 wherein said crosslinking agent is a bis(diallylammonium)dialkylene ion.
- 15 12. The method of Claim 1 wherein the polymer is a homopolymer.
13. A method of Claim 1 wherein the polymer is a copolymer.

-27-

14. A method of Claim 13 wherein the copolymer comprises the monomers diallylamine, allylamine, and triallylamine.
15. A method of Claim 13 wherein the copolymer comprises the monomers diallylamine and allylamine.
- 5 16. A pharmaceutical composition comprising:
 - a) a first amount of an unsubstituted polydiallylamine polymer;
 - b) a second amount of a cholesterol-lowering agent wherein said first and second amounts together comprise an effective amount; and
 - c) optionally, a pharmaceutically acceptable carrier.
- 10 17. The composition of Claim 16 wherein the cholesterol-lowering agent is selected from the group consisting of: fibrates, nicotinic acid and derivatives thereof, Acifran, Azacosterol, Benfluorex, β -Benzalbutyramide, Carnitine, Chondroitin Sulfate, Clomestron, Detaxtran, Dextran Sulfate Sodium, 5,8,11,14,17-Eicosapentaenoic Acid, Eritadenine, Furazabol, Meglutol,
15 Melinamide, Mytatrienediol, Ornithine, γ -Oryzanol, Pantethine, Pentaerythritol Tetraacetate, α -phenybutyramide, Priozaadil, Probucol, B-Sitosterol, Sultosilic Acid, Piperazine Salt, Tiadenol, Triparanol, Xenbucin, and combinations thereof.
18. The composition of Claim 16 wherein the cholesterol-lowering agent is a
20 fibrate.
19. The composition of Claim 18 wherein the fibrate is Clofibrate, Gemfibrozil, Fenofibrate, Bezafibrate or combinations thereof.
20. The composition of Claim 16 wherein the cholesterol-lowering agent is Niacin.

21. The composition of Claim 16 wherein the cholesterol-lowering agent is Probucol.
22. The composition of Claim 16 wherein the unsubstituted polydiallylamine is characterized by one or more monomeric units of the formulae:

5



or a combination thereof and salts thereof.

23. The composition of Claim 16 wherein said polymer is crosslinked by means of a multifunctional crosslinking agent, said agent being present in an amount from about 0.5-50% by weight, based upon the combined weight of monomer and crosslinking agent.
24. The composition of Claim 23 wherein said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
25. The composition of Claim 23 wherein said crosslinking agent comprises epichlorohydrin.
26. The composition of Claim 23 wherein said crosslinking agent is a bis(diallylammonium)dialkylene ion.
27. The composition of Claim 16 wherein the polymer is a homopolymer.

28. A composition of Claim 16 wherein the polymer is a copolymer.
 29. A composition of Claim 28 wherein the copolymer comprises the monomers diallylamine, allylamine, and triallylamine.
 30. A composition of Claim 28 wherein the copolymer comprises the monomers diallylamine and allylamine.
- 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10568

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/785 A61K45/06 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 29107 A (GELTEX PHARMACEUTICALS) 9 July 1998 (1998-07-09) claims 1-3,15 page 11, line 27-31 page 12, line 13-16	1,8-10, 12,13
A	GB 2 329 334 A (RECKITT & COLMAN PRODUCTS) 24 March 1999 (1999-03-24) claims 1,3,6	1-4

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

22 February 2000

Date of mailing of the international search report

29/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

Information on patent family members



International Application No

PCT/US 99/10568

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9829107 A	09-07-1998	AU 5621098 A	31-07-1998
GB 2329334 A	24-03-1999	NONE	

21. The composition of Claim 16 wherein the cholesterol-lowering agent is Probucol.
22. The composition of Claim 16 wherein the unsubstituted polydiallylamine is characterized by one or more monomeric units of the formulae:

5



or a combination thereof and salts thereof.

23. The composition of Claim 16 wherein said polymer is crosslinked by means of a multifunctional crosslinking agent, said agent being present in an amount from about 0.5-50% by weight, based upon the combined weight of monomer and crosslinking agent.
24. The composition of Claim 23 wherein said crosslinking agent is present in an amount from about 2.5-20% by weight, based upon the combined weight of monomer and crosslinking agent.
25. The composition of Claim 23 wherein said crosslinking agent comprises epichlorohydrin.
26. The composition of Claim 23 wherein said crosslinking agent is a bis(diallylammonium)dialkylene ion.
27. The composition of Claim 16 wherein the polymer is a homopolymer.

-29-

28. A composition of Claim 16 wherein the polymer is a copolymer.
 29. A composition of Claim 28 wherein the copolymer comprises the monomers diallylamine, allylamine, and triallylamine.
 30. A composition of Claim 28 wherein the copolymer comprises the monomers diallylamine and allylamine.
- 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10568

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/785 A61K45/06 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 29107 A (GELTEX PHARMACEUTICALS) 9 July 1998 (1998-07-09) claims 1-3,15 page 11, line 27-31 page 12, line 13-16	1,8-10, 12,13
A	GB 2 329 334 A (RECKITT & COLMAN PRODUCTS) 24 March 1999 (1999-03-24) claims 1,3,6	1-4

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 February 2000

Date of mailing of the international search report

29/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 MV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Peeters, J

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/10568

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9829107 A	09-07-1998	AU 5621098 A	31-07-1998
GB 2329334 A	24-03-1999	NONE	

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 December 2000 (07.12.2000)

PCT

(10) International Publication Number
WO 00/72825 A1

- (51) International Patent Classification⁷: **A61K 9/14**,
9/48, 47/32, 47/38, A61P 3/04
- (21) International Application Number: PCT/US00/14106
- (22) International Filing Date: 23 May 2000 (23.05.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/320,188 29 May 1999 (29.05.1999) US
- (71) Applicant: **ABBOTT LABORATORIES** [US/US];
D377/AP6D, 100 Abbott Park Road, Abbott Park, IL
60064-6050 (US).
- (72) Inventors: **LAW, Devalina**; 835C Country Club Drive,
Libertyville, IL 60048 (US). **KRILL, Steven, L.**; 44 Mey-
ersville Road, Chatham, NJ 07928 (US). **SCHMITT, Eric**,
A.; 319 Evergreen Court, Libertyville, IL 60048 (US).
FORT, James, J.; 2700 Leaffield Terrace, Midlothian, VA
23113 (US).
- (74) Agents: **SICKERT, Dugal, S. et al.**; D377/AP6D, 100
Abbott Park Road, Abbott Park, IL 60064-6050 (US).
- (81) Designated States (*national*): CA, JP, MX.
- (84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 00/72825 A1

(54) Title: NOVEL FORMULATIONS COMPRISING LIPID-REGULATING AGENTS

(57) Abstract: The present invention is directed to a solid formulation comprising the lipid-regulating agent dispersed in a hydrophilic, amorphous polymer in which said lipid-regulating agent is present as a meta-stable, amorphous phase.

Novel Formulations Comprising Lipid-Regulating Agents

Field of the Invention

5

The present invention relates to novel formulations comprising lipid-regulating agents.

10

Background of the Invention

15

2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.

20

Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726. U.S. Patent No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant.

25

30

35

U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix. The formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.

European Patent Application No. EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granules thus produced are dried.

PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch. The neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.

U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon. The carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.

Sheu, M. T., et al, *Int. J. Pharm.* 103 (1994) 137-146, reported that a dispersion of fenofibrate in PVP still maintains the same crystalline form of the drug itself.

Palmieri, G. F., et al, *Pharma Sciences* 6 (1996) 188-194, reported that a dispersion of crystalline fenofibrate could be prepared in PEG 4000. The authors concluded solid solutions in PEG are formed when the amount of fenofibrate is less than 15% and the dissolution rate is increased, particularly for the 90/10 carrier/drug ratio.

Gemfibrozil is another member of the fibrate class of lipid-regulating agents. U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach. The first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative, and the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceutically-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceutically-acceptable (meth)acrylate copolymer prior to admixture with the first granulation. The first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.

U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid-disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid-insoluble polymer.

Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members. U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as pravastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as

microcrystalline cellulose (dry binder) or
polyvinylpyrrolidone (wet binder), one or more
disintegrating agents such as croscarmellose sodium, one or
more lubricants such as magnesium stearate and one or more
5 basifying agents such as magnesium oxide.

It is an object of the present invention to provide
formulations of lipid-regulating agents having enhanced
bioavailability when compared to commercially available
10 formulations.

Summary of the Invention

15 The present invention is directed to a solid
formulation comprising the lipid-regulating agent dispersed
in a hydrophilic, amorphous polymer in which said lipid-
regulating agent is present as a metastable, amorphous
phase. The size reduction obtained through the preparation
20 of a dispersion is usually difficult to obtain. However, by
using any technique that results in the dispersion of the
lipid-regulating agent in an amorphous polymer, such as, for
example, solvent evaporation or fusion, results in an
increase in the dissolution rate and oral bioavailability of
25 the said lipid-regulating agent.

The formulation may be administered directly, diluted
into an appropriate vehicle for administration, encapsulated
into hard gelatin shells or capsules, or compressed into
30 tablets, for administration, or administered by other means
obvious to those skilled in the art.

Brief Description of the Drawings

Figure 1 is a graph showing the plasma concentration in fed dogs of the formulation of Example 1 and a reference compound.

Detailed Description of the Invention

10

The bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.

15

The composition comprising the lipid-regulating agent is prepared by dissolving or dispersing the lipid-regulating agent and hydrophilic, amorphous polymer in a sufficient amount of solvent. The solvent is evaporated to yield a solid mass which is ground, sized and optionally formulated into an appropriate delivery system. Other techniques, known in the art, such as for example fusion or fusion-evaporation, may also be used.

25

The delivery system of the present invention results in increased solubility and bioavailability, and improved dissolution rate of the lipid-regulating agent.

30

If the solvent evaporation technique is used, suitable solvents include, for example, lower alkyl alcohols such as methanol, ethanol, or any other pharmaceutically-acceptable organic solvent in which the lipid-regulating agent and the polymers have appreciable solubility.

35

Suitable hydrophilic, amorphous polymers include, for example, polyvinylpyrrolidone (PVP),

hydroxypropylmethylcellulose (HPMC), or other pharmaceutically-acceptable hydrophilic, amorphous polymers such as for example, Eudragits®.

5 Other pharmaceutically-acceptable excipients may be added to the formulation prior to forming the desired final product. Suitable excipients include, for example, lactose, starch, magnesium stearate, or other pharmaceutically-acceptable fillers, diluents, lubricants, disintegrants, etc., that might
10 be needed to prepare a capsule or tablet.

 The resulting composition comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral
15 administration, filled into capsules, or made into tablets for oral administration, or delivered by some other means obvious to those skilled in the art. The said composition can be used to improve the oral bioavailability and solubility of said lipid-regulating agent.

20

 The invention will be understood more clearly from the following non-limiting representative examples:

Example 1

25

 A mixture (3 g) of fenofibrate and PVP (PF 17) in a ratio of 15:85 was dissolved in 4.5 mL of ethanol. The ethanol was evaporated under vacuum at 85°C. The resulting dry solid was then ground and sized through a 60-100 mesh
30 screen. 446.7 mg of the granular formulation (containing 67 mg fenofibrate) was filled into individual capsules.

Example 2

35

 A mixture (3 g) of statin and PVP (PF 17) in a ratio of 15:85 is dissolved in sufficient ethanol. The ethanol is

evaporated under vacuum at 85°C. The resulting dry solid is then ground and sized through a 60-100 mesh screen. The solid is then filled in capsules to obtain the desired unit dose.

5

Example 3

Capsules prepared by the process described in Example 1, and from a commercial fenofibrate composition, Lipanthyl 67M (Groupe Fournier) (Reference), were administered to a group of dogs at a dose of 67 mg fenofibrate/dog. The plasma concentrations of fenofibric acid were determined by HPLC. Concentrations were normalized to a 6.7 mg/kg dose in each dog. Figure 1 presents the resulting data in graph form. The results provided as mean \pm SD, n=6, were as follows:

Lipanthyl 67M (Reference):
Cmax = 4.06 \pm 0.53 mcg/ml
Tmax = 1.0 \pm 0.0 hr
t_{1/2} = 9.5 hr
AUC (0-24) = 21.37 \pm 2.56 mcg•hr/ml

Capsule of Example 1:
Cmax = 2.22 \pm 0.31 mcg/ml
Tmax = 2.3 \pm 1.2
t_{1/2} = 7.7 hr
AUC (0-24) = 18.04 mcg•hr/ml
AUC relative to reference = 84.4%

Claims


1. A composition comprising a lipid-regulating agent dissolved or dispersed in a hydrophilic, amorphous polymer in which said lipid-regulating agent is present as a meta-stable, amorphous phase.
2. A composition of claim 1 wherein said lipid-regulating agent is a fibrate.
3. A composition of claim 2 wherein said fibrate is fenofibrate.
4. A composition of claim 1 wherein said lipid-regulating agent is a statin.
5. A composition of claim 4 wherein said statin is prevastatin.
6. A composition of claim 4 wherein said statin is atorvastatin.
7. A composition of claim 1 further comprising dissolving the lipid-regulating agent into a hydrophilic, amorphous polymer in a sufficient amount of solvent, then removing said solvent to yield a solid composition comprising said lipid-regulating agent in a stable, amorphous phase.
8. A composition of claim 7 wherein at least one or more of said solvents is selected from lower alkyl alcohol such as for example, methanol, ethanol, or any other pharmaceutically-acceptable organic solvent in which the lipid-regulating agent and the polymer have appreciable solubility.

9. A composition of claim 8 wherein one or more of said solvents is ethanol.
10. A composition of claim 1 wherein at least one or more
5 of said hydrophilic polymers is selected from polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), or other pharmaceutically-acceptable hydrophilic, amorphous polymers such as for example, Eudragits®.
- 10 11. A composition of claim 10 wherein at least one or more of said hydrophilic polymers is polyvinylpyrrolidone.
12. A delivery system comprising a composition of claim 1.
- 15 13. A delivery system of claim 12 wherein said delivery system is a capsule or tablet.
14. A method of treating hyperlipidemia comprising the
20 administration of a composition of claim 1 to a patient.
15. A method of treating hyperlipidemia comprising the
25 administration of a composition of claim 3 to a patient.
16. A method of treating hyperlipidemia comprising the
30 administration of a composition of claim 13 to a patient.

FIG. 1

Insert dog data

Mean (\pm SEM, n=3) Plasma Concentrations of Fenofibric Acid
after a 67 mg Oral Dose of Fenofibrate in Non-fasted Dogs



INTERNATIONAL SEARCH REPORT

Internal Application No

PCT/US 00/14106

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/14 A61K9/48 A61K47/32 A61K47/38 A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 36318 A (LEK TOVARNA FARMACEVTSKIH ;REBIC LJUBOMIRA BARBARA (SI); KERC JANE) 21 November 1996 (1996-11-21) page 4, paragraph 2 page 5, last paragraph -page 6, paragraph 2 page 10, paragraph 3 claims 2,7	1-3,7-16
X	EP 0 462 066 A (WARNER LAMBERT CO) 18 December 1991 (1991-12-18) page 2, line 28 -page 3, line 7; claims; example 1 --- -/--	1,2, 10-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

8 document member of the same patent family

Date of the actual completion of the international search

1 September 2000

Date of mailing of the international search report

12/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/14106

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 31361 A (FOURNIER LAB SA) 23 July 1998 (1998-07-23) page 5, line 22 - last line page 6, line 21 -page 7, line 7 page 10, line 26 -page 11, line 3; claims 1-3,13,14; example 1</p> <p style="text-align: center;">---</p>	1-3,7-13
X	<p>MORRIS K A ET AL: "Characterization of humidity-dependent changes in crystal properties of a new HMG-CoA reductase inhibitor in support of its dosage form development." INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 108, no. 3, 1994, pages 195-206, XP000929694 ISSN: 0378-5173 page 196, column 1, paragraph 3 page 197, column 2, last paragraph -page 198, column 1, paragraph 1 page 201, column 1, last paragraph -column 2, line 1 page 204, column 2, paragraph 2</p> <p style="text-align: center;">---</p>	1,7,12, 13
X	<p>WO 98 15264 A (LOEFROTH JAN ERIK ;ASTRA AB (SE); OEDMAN JONAS (SE)) 16 April 1998 (1998-04-16) page 7, line 9 -page 9, line 8 page 9, line 22 - line 26; claims 1-6,9,10,12; example 5</p> <p style="text-align: center;">-----</p>	1,4,7-16

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-16 relate to a compound defined by reference to a desirable characteristic or property, namely a "lipid-regulating agent". The term "lipid-regulating agent" as used in the present independent claims 1, 12, 14-15 and in dependent claims 2-11, and 13 defines the active agent by its pharmacological effect. However, a compound cannot be sufficiently characterised by its pharmacological effect as it is done by an expression like "lipid-regulating agent", because it is impossible to know which substances are encompassed in this expression. Moreover, a compound cannot be sufficiently characterised by the term "regulating", because this term has no well-recognised meaning and is therefore unclear.

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for the concept of "lipid-regulating agent" and those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds mentioned in claims 2-6.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interns al Application No

PCT/US 00/14106

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9636318 A	21-11-1996	SI 9500173 A	31-12-1996
		AU 698360 B	29-10-1998
		AU 5710396 A	29-11-1996
		CZ 9703655 A	15-04-1998
		EP 0827397 A	11-03-1998
		HU 9901457 A	30-08-1999
		JP 11505542 T	21-05-1999
		PL 323487 A	30-03-1998
		SK 153497 A	08-04-1998
		US 6042847 A	28-03-2000
EP 0462066 A	18-12-1991	AU 7837891 A	19-12-1991
		CA 2044509 A	16-12-1991
		FI 912883 A	16-12-1991
		JP 4230215 A	19-08-1992
		NO 912303 A	16-12-1991
		PT 97988 A	31-03-1992
		ZA 9104586 A	29-04-1992
WO 9831361 A	23-07-1998	FR 2758459 A	24-07-1998
		AU 5336798 A	07-08-1998
		BR 9806738 A	29-02-2000
		CA 2219475 A	17-07-1998
		CZ 9902535 A	17-11-1999
		EP 0952829 A	03-11-1999
		NO 993519 A	16-09-1999
		PL 334748 A	13-03-2000
		US 6074670 A	13-06-2000
		ZA 9800324 A	12-08-1998
WO 9815264 A	16-04-1998	AU 4578097 A	05-05-1998
		EP 0948320 A	13-10-1999